Grupo Oncoclinicas
Grupo Oncoclinicas is the largest cancer treatment network in Latin America, operating 140+ oncology clinics and precision medicine laboratories across 40 Brazilian cities and serving insured patients through 70+ contracted health plans, currently in financial restructuring.
- Company typePublic
- Founded2010
- HeadquartersBelo Horizonte, Brazil
- Headcount1,001–5,000
- GTM typeB2C
- OfferingServices
What Grupo Oncoclinicas does
Grupo Oncoclinicas (Oncoclínicas&Co, B3: ONCO3) is a publicly traded Brazilian oncology care platform founded in 2010 by oncologist Bruno Ferrari in Belo Horizonte. The company operates the largest cancer treatment network in Latin America with 140+ clinics, laboratories, and integrated cancer centers across 40 Brazilian cities, employing over 2,700 medical professionals. Service lines span the full oncology continuum — chemotherapy, radiotherapy, immunotherapy, targeted therapy, bone marrow transplant, oncological surgery, and palliative care — delivered alongside a dedicated precision medicine arm, OC Medicina de Precisão, which integrates pathological anatomy, genomics, and Big Data laboratories to support diagnosis and treatment selection via molecular journeys. Adjacent revenue streams include DeLife (oral oncology medications), OC Vacinas (vaccination program launched April 2024), clinical research across seven units since 2018, the OC Telemedicina platform, and the OC Franquias franchise channel.
The business model is B2B2C: services are billed primarily through contracted health insurance (convênio) providers — over 70 plans including UNIMED, Bradesco, SulAmérica, Porto Seguro, and Amil — with supplementary private-pay and telemedicine revenue. Go-to-market is sales-led via direct clinic access, enterprise contracts with insurers, and a multi-channel patient acquisition stack including a proprietary mobile app, telemedicine platform, social media presence, and an educational content engine. Distribution is complemented by an exclusive clinical research partnership with Dana-Farber Cancer Institute (Harvard Medical School affiliate) and certified laboratory operations under ONA Level 3, PALC, PICQ, and PACQ accreditations.
As of early 2026, the company is in severe financial distress: founder-CEO Bruno Ferrari stepped down in February 2026 amid governance concerns tied to Banco Master and a near-50% stock decline, CFO Camille Faria departed shortly after, and net debt stands at approximately R$4 billion with EBITDA turning deeply negative in 2025. A proposed R$1 billion+ investment from insurer Porto Saúde and diagnostics group Fleury — alongside plans to file for judicial (creditor) recovery in April 2026 — frames the company as a turnaround/restructuring candidate despite its leading operational footprint.
Grupo Oncoclinicas firmographics
Firmographics- Name
- Grupo Oncoclinicas
- Legal name
- ONCOCLINICAS DO BRASIL SERV MEDICOS SA
- Website
- https://grupooncoclinicas.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Grupo Oncoclinicas is the largest cancer treatment network in Latin America, operating 140+ oncology clinics and precision medicine laboratories across 40 Brazilian cities and serving insured patients through 70+ contracted health plans, currently in financial restructuring.
- Ownership category
- akta.pro rank
Grupo Oncoclinicas industry classification
Industry- Product category
- Oncology Healthcare Services
- NAICS
- Ambulatory Health Care Services (621), Offices of Physicians (62111), Medical and Diagnostic Laboratories (6215), Other Ambulatory Health Care Services (6219)
- SIC
- Services-Health Services (8000), Services-Specialty Outpatient Facilities, Nec (8093), Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)
- akta.pro secondary industries
- Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Medical Oncology (HLAKAFAB), Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)
Keywords
Where Grupo Oncoclinicas is headquartered
LocationHeadquarters
- HQ city
- Belo Horizonte
- HQ country
- Brazil
- HQ region
- Latin America
Offices5 records
Markets served
Grupo Oncoclinicas business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Supply Chain, Others
Revenue model
- Healthcare Services Revenue: Oncoclinicas generates revenue primarily through providing oncology services including consultations, chemotherapy, radiotherapy, surgery, diagnostics, and specialized cancer treatments through its network of 140+ clinics. Services are billed primarily through health insurance (convênio) providers and some private pay patients.
- Diagnostic Testing: Revenue from pathology, genomic testing, and molecular diagnostics services performed at the OC Medicina de Precisão laboratories, serving both internal patients and external referring physicians.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Grupo Oncoclinicas product offering
Product offeringCore offering
Grupo Oncoclinicas operates one of Latin America's largest oncology service networks, delivering comprehensive cancer care through 140+ clinics, laboratories, and integrated treatment centers across 40 Brazilian cities. The company provides end-to-end oncology services including precision medicine (pathological anatomy, genomics, and big data diagnostics), chemotherapy, radiotherapy, oncological surgery, immunotherapy, targeted therapy, bone marrow transplant, palliative care, and clinical research programs, supported by a proprietary telemedicine platform and contracted with 70+ health insurance providers.
Product overview
Oncoclinicas&Co is a comprehensive oncology services platform operating as a network of over 140 units (clinics, hospitals, and laboratories) across 40 cities in Brazil. The offering is organized around integrated care delivery combining a core platform of diagnostic and treatment services with specialized precision medicine capabilities. The main product pillars include: OC Medicina de Precisão (central precision medicine hub with pathological anatomy, genomics, and big data labs), OC Linha de Cuidado (care coordination service), comprehensive treatment services (chemotherapy, radiotherapy, immunotherapy, targeted therapy, bone marrow transplant, and oncological surgery), clinical research program, telemedicine platform (OC Telemedicina), and supportive services including DeLife (oral medications), OC Vacinas (vaccination), palliative care, and professional education (OC Academia, OC Journal). The network operates under a hub-and-spoke model with flagship Cancer Centers and franchise locations (OC Franquias).
Differentiator
Problem solved
Functional benefit
Brands
- OC Medicina de Precisão: Precision Medicine Center encompassing Pathological Anatomy, Genomics and Big Data laboratories for diagnosis and prognosis
- OC Linha de Cuidado
- OC Vacinas
- DeLife
- OC Telemedicina
- OC Cuidados Paliativos
- Programa de Pesquisa Clínica
Products and services
- OC Medicina de Precisão (Precision Medicine Center) Comprehensive precision medicine center encompassing Pathological Anatomy, Genomics, and Big Data laboratories offering a complete molecular portfolio (immunohistochemistry, NGS panels, liquid biopsy, germline testing, digital pathology) for diagnostic, predictive, and prognostic purposes in oncology.
- OC Linha de Cuidado (Care Line) Continuous care coordination service that accompanies cancer patients throughout their treatment journey from diagnosis to clinical outcome, providing agility in exams, radiotherapy, surgeries, consultations, and diagnostic procedures.
- OC Vacinas (Vaccination Program) Vaccination service for patients and family members at affiliated Oncoclinicas units, focused on disease prevention and increased vaccination coverage in line with national guidelines.
- Clinical Research Program Clinical research program with centralized management across seven units in Brazil, contributing to scientific development and providing access to innovative oncology treatments for patients.
- OC Telemedicina (Telemedicine)
Quantifiable outcome
- Largest oncology group in Latin America with 140+ units
- +1 more outcomes
Companies that use Grupo Oncoclinicas
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Grupo Oncoclinicas technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Grupo Oncoclinicas partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Dana-Farber Cancer InstitutecoreExclusive partnership in Brazil with Dana-Farber Cancer Institute, affiliated with Harvard Medical School - one of the world's leading cancer treatment and research centers. This partnership supports clinical research, knowledge exchange, and access to cutting-edge oncology practices.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Grupo Oncoclinicas competitors and assessment
Company assessmentDirect peers
- Oncologia D'Or: Direct competitor within the top 3 oncology groups in Brazil, backed by Rede D'Or São Luiz. Operates cancer treatment centers competing with Oncoclinicas for the same patient population, health insurance contracts, and specialist physicians across Brazilian cities.
- Rede Américas: Third member of Brazil's top 3 oncology groups (alongside Oncoclinicas and Oncologia D'Or). Operates oncology clinics and treatment centers with similar patient mix, payer relationships, and competitive positioning in the same Brazilian private oncology market.
- A.C. Camargo Cancer Center: One of Brazil's leading cancer specialty hospitals, providing comprehensive oncology diagnosis, treatment, and research. Comparable to Oncoclinicas in oncology specialization, with similar clinical research programs and multidisciplinary care model, though operating as a single flagship institution rather than a distributed network.
Broad incumbents
- Rede D'Or São Luiz: Brazil's largest hospital chain and parent of Oncologia D'Or. While a broad incumbent across many specialties, Rede D'Or's dedicated oncology arm makes it a major competitor for cancer patients and specialists in the same Brazilian market.
- Fleury Group: Major Brazilian diagnostic and laboratory medicine company currently negotiating a co-investment with Porto Saúde in Oncoclinicas. Competes with Oncoclinicas' OC Medicina de Precisão division in pathology, genomics, and diagnostic testing while also serving as a referral partner.
- Dasa (Diagnósticos da América): Latin America's largest medical diagnostic company, competing directly with Oncoclinicas' OC Medicina de Precisão in clinical laboratory, imaging, and molecular/genomic testing services. Operates across Brazil with similar B2B and B2C diagnostic offerings.
- Hospital Israelita Albert Einstein: Premium Brazilian hospital system offering comprehensive oncology services including diagnosis, treatment, and research. Competes with Oncoclinicas for high-end private patients and specialist physicians, though positioned more broadly across multiple specialties.
- Hospital Sírio-Libanês: High-end São Paulo-based hospital offering strong oncology programs alongside other specialties. Competes for the same private insured patient segment and employs many of the same specialist physicians as Oncoclinicas in the premium oncology market.
Others
- UnitedHealth Group (Amil): Major US-based health insurer operating Amil in Brazil, one of the largest payers in Oncoclinicas' network. Not a direct clinical competitor but a critical payer and increasingly vertically integrated into care delivery, potentially conflicting with Oncoclinicas' independent provider model.
Regional players
- MD Anderson Cancer Center: World-leading US-based cancer specialty hospital and research center, serving as the global benchmark for comprehensive oncology care. Comparable in care model (multidisciplinary, research-driven, precision medicine-enabled) though operating in a different geography and serving as an aspirational peer rather than a direct competitor.
Market position
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Grupo Oncoclinicas social profiles
Digital presenceGrupo Oncoclinicas compliance and trust
Trust signalCompliance6 records
Grupo Oncoclinicas financial estimates
Financial estimateRevenue estimate
Valuation estimate
Grupo Oncoclinicas leadership team
Management profileNumber of profiles
Profiles6 records
Grupo Oncoclinicas subsidiaries and ownership
Company hierarchySubsidiaries2 records
Grupo Oncoclinicas funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Grupo Oncoclinicas M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Grupo Oncoclinicas
What does Grupo Oncoclinicas do?
Grupo Oncoclinicas operates one of Latin America's largest oncology service networks, delivering comprehensive cancer care through 140+ clinics, laboratories, and integrated treatment centers across 40 Brazilian cities. The company provides end-to-end oncology services including precision medicine (pathological anatomy, genomics, and big data diagnostics), chemotherapy, radiotherapy, oncological surgery, immunotherapy, targeted therapy, bone marrow transplant, palliative care, and clinical research programs, supported by a proprietary telemedicine platform and contracted with 70+ health insurance providers.
Is Grupo Oncoclinicas a public or private company?
Grupo Oncoclinicas is a public company. It is classified as public and is currently operating.
When was Grupo Oncoclinicas founded?
Grupo Oncoclinicas was founded in 2010. It employs 1,001 to 5,000 people.
Where is Grupo Oncoclinicas based?
Grupo Oncoclinicas is headquartered in Belo Horizonte, Brazil, in the Latin America region.
How does Grupo Oncoclinicas make money?
Two revenue lines are on record. Healthcare Services Revenue is the primary driver. The others are diagnostic Testing.
Who are Grupo Oncoclinicas's main competitors?
Direct peers on record are Oncologia D'Or, Rede Américas and A.C. Camargo Cancer Center. Broad incumbents are Rede D'Or São Luiz, Fleury Group, Dasa (Diagnósticos da América), Hospital Israelita Albert Einstein and Hospital Sírio-Libanês. UnitedHealth Group (Amil) is listed as an others. MD Anderson Cancer Center is listed as a regional player.
Does Grupo Oncoclinicas have an API?
No public API is recorded for Grupo Oncoclinicas.
What industry is Grupo Oncoclinicas in?
Grupo Oncoclinicas's product category is Oncology Healthcare Services. Its primary akta.pro industry code is HLAFABAI, Ambulatory Oncology Centers (Outpatient Chemo/Radiation), with a secondary code of HLAFAAAM, Hospital-Integrated Cancer Centers (Acute Oncology Programs). Its NAICS code is 621 and its SIC code is 8000.